Paradoxical reactions to targeted biological treatments: A way to treat and trigger?
Brunasso
Alexandra M G
AM
Laimer
Martin
M
Massone
Cesare
C
D000069594:Abatacept; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000009:adverse effects*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects; D007074:Immunoglobulin G / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced* / Q000473:pathology; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001688:Biological Products; D018796:Immunoconjugates; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069594:Abatacept; D000069285:Infliximab; D000068800:Etanercept; C472181:efalizumab